Lincoln National Corp’s Clearside Biomedical CLSD Stock Holding History

Lincoln National Corp’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,153	Closed	-$96K	–	1031
2023 Q1	$96K	Hold	6,153	–	–	﹤0.01%	957
2022 Q4	$103K	Hold	6,153	–	–	﹤0.01%	896
2022 Q3	$104K	Buy	+6,153	New	+$135K	﹤0.01%	841

Other funds holding CLSD

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Lincoln National Corp's CLSD Position: Q2 2023 in Review

Lincoln National Corp sold out of Clearside Biomedical (CLSD) in Q2 2023, closing a stake of 6,153 shares — an estimated $96K sold.

Lincoln National Corp first reported a position in CLSD in Q3 2022 and held it in 3 quarters. The position peaked at $104K in Q3 2022. 54 funds tracked by Wall St. Rank hold CLSD as of Q2 2023.

Lincoln National Corp reported no remaining Clearside Biomedical position as of Q2 2023 after selling out during the quarter.
Lincoln National Corp sold 6,153 Clearside Biomedical shares in Q2 2023, an estimated $96K.
Lincoln National Corp first reported a position in Clearside Biomedical in Q3 2022 and held it in 3 quarters.
Lincoln National Corp's Clearside Biomedical position peaked at $104K in Q3 2022.
54 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2023.

Based on Lincoln National Corp's 13F filing for Q2 2023, filed 7 Aug 2023.